VEGFA and neoplasm: Bevacizumab, a humanized monoclonal antibody inhibiting VEGF, enhances tumor-specific immune response by promoting immunosuppressive tumor microenvironment, normalizing vascular structure, increasing T cell infiltration, and activating local immune microenvironment [12, 33–36].